Get the Stockscreener App
87.22
0.42%
-0.37
Pre-market:
88.10
0.88
+1.01%
Arcellx Inc stock is traded at $87.22, with a volume of 333.07K.
It is down -0.42% in the last 24 hours and down -9.95% over the past month.
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
See More
Previous Close:
$87.59
Open:
$86.87
24h Volume:
333.07K
Relative Volume:
0.64
Market Cap:
$4.72B
Revenue:
$144.75M
Net Income/Loss:
$-53.89M
P/E Ratio:
-22.03
EPS:
-3.96
Net Cash Flow:
$-42.88M
1W Performance:
-12.90%
1M Performance:
-9.95%
6M Performance:
+60.45%
1Y Performance:
+65.75%
1-Day Range:
$83.69
$88.30
1-Week Range:
$83.69
$100.33
52-Week Range:
$46.42
$107.37
Arcellx Inc Stock (ACLX) Company Profile
Name
Arcellx Inc
Sector
Industry
Phone
240-327-0603
Address
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ACLX | 87.22 | 4.72B | 144.75M | -53.89M | -42.88M | -3.96 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-04-24 | Reiterated | Needham | Buy |
| Dec-19-23 | Initiated | Scotiabank | Sector Outperform |
| Oct-30-23 | Initiated | TD Cowen | Outperform |
| Oct-17-23 | Initiated | UBS | Buy |
| May-18-23 | Initiated | Truist | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
| Mar-14-23 | Initiated | Stifel | Buy |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-13-22 | Resumed | BofA Securities | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-27-22 | Initiated | Needham | Buy |
| Jul-20-22 | Initiated | Canaccord Genuity | Buy |
| Mar-01-22 | Initiated | BofA Securities | Buy |
| Mar-01-22 | Initiated | SVB Leerink | Outperform |
View All
Arcellx Inc Stock (ACLX) Latest News
arcellx CFO Michelle Gilson sells $156,508 in shares By Investing.com - Investing.com Canada
arcellx CFO Michelle Gilson sells $156,508 in shares - Investing.com India
Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year? - MSN
First Turn Management LLC Makes New $17.90 Million Investment in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Position Reduced by Victory Capital Management Inc. - MarketBeat
First Week of January 2025 Options Trading For Arcellx (ACLX) - Nasdaq
Arcellx, Inc. (NASDAQ:ACLX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Arcellx (NASDAQ:ACLX) Shares Down 6.4%What's Next? - MarketBeat
Paradigm Biocapital Advisors LP Acquires Significant Stake in Ar - GuruFocus.com
Perceptive Advisors LLC Adjusts Position in Arcellx Inc - GuruFocus.com
arcellx director Kavita Patel sells $159,495 in stock - Investing.com
Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice - Yahoo Finance
FMR LLC Adjusts Stake in Arcellx Inc - GuruFocus.com
arcellx CFO Michelle Gilson sells $1.24 million in stock By Investing.com - Investing.com South Africa
Arcellx director Kavita Patel sells $5.97 million in stock - Investing.com
arcellx CFO Michelle Gilson sells $1.24 million in stock - Investing.com
Arcellx director Kavita Patel sells $5.97 million in stock By Investing.com - Investing.com UK
US Bancorp DE Acquires 2,851 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights - Defense World
Objective long/short (ACLX) Report - Stock Traders Daily
Piper Sandler Forecasts Strong Price Appreciation for Arcellx (NASDAQ:ACLX) Stock - Defense World
Arcellx Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
HC Wainwright Has Optimistic Outlook of Arcellx Q3 Earnings - Defense World
Analyst Expectations For Arcellx's Future - Benzinga
Arcellx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Arcellx (NASDAQ:ACLX) Hits New 1-Year High on Analyst Upgrade - Defense World
Arcellx earnings missed by $0.14, revenue fell short of estimates - Investing.com UK
HC Wainwright Estimates Arcellx's Q3 Earnings (NASDAQ:ACLX) - MarketBeat
HC Wainwright Boosts Arcellx (NASDAQ:ACLX) Price Target to $95.00 - Defense World
Needham & Company LLC Reiterates Buy Rating for Arcellx (NASDAQ:ACLX) - Defense World
Morgan Stanley Forecasts Strong Price Appreciation for Arcellx (NASDAQ:ACLX) Stock - Defense World
Bank of America Raises Arcellx (NASDAQ:ACLX) Price Target to $100.00 - Defense World
Arcellx : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q) - Marketscreener.com
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights - BioSpace
Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar? - MSN
Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Arcellx stock soars to all-time high of $97.61 amid robust growth - Investing.com India
Arcellx (NASDAQ:ACLX) Hits New 52-Week High on Analyst Upgrade - MarketBeat
Arcellx (ACLX) Releases Clinical Data from Phase 1 and iMMagine-1 Studies for Multiple Myeloma Patients On November 5, 2024, Arcellx, Inc. (NASDAQ: ACLX) made public an abstract containing fresh clinical data from its Phase 1 and iMMagine-1 - Defense World
Arcellx price target raised to $106 from $81 at Morgan Stanley - Yahoo Finance
How Arcellx (ACLX) Stock Stands Out in a Strong Industry - MSN
ASH ’24: Arcellx Mounts Strong Challenge To Myeloma CAR-T Rival Carvykti - Citeline News & Insights
Arcellx stock target increased, rating held on positive trial data - Investing.com
Arcellx (NASDAQ:ACLX) Receives Buy Rating from Needham & Company LLC - MarketBeat
Arcellx (NASDAQ:ACLX) Price Target Raised to $100.00 - MarketBeat
Arcellx (NASDAQ:ACLX) Price Target Raised to $106.00 at Morgan Stanley - MarketBeat
Robert W. Baird Issues Positive Forecast for Arcellx (NASDAQ:ACLX) Stock Price - MarketBeat
HC Wainwright Increases Arcellx (NASDAQ:ACLX) Price Target to $95.00 - MarketBeat
Gilead, Arcellx Tout Best-in-Class Potential for CAR T Therapy in Multiple Myeloma - BioSpace
Arcellx shares target upgraded, maintains buy on positive trial data By Investing.com - Investing.com South Africa
Arcellx stock target increased, rating held on positive trial data By Investing.com - Investing.com UK
Arcellx Inc Stock (ACLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):